Introduction: Inhibitor of growth 4 (ING4) is a tumor suppressor. However the role of ING4 in human bladder malignancy is unknown. In this study, ING4 expression in human bladder cancer and its potential effects were studied. Materials and Methods: ING4 expression in 47 human bladder cancer tissues and paired adjacent normal tissues was detected by Western blotting, quantitative reverse transcription-polymerase chain reaction, and immunohistochemistry. The migration and cell cycle progression of SV-HUC-1 and T24 cells with aberrant ING4 expression were examined. Results: ING4 protein and mRNA were significantly decreased in bladder cancer tissues. ING4 protein level was significantly lower in the group of patients over 50 years of age. ING4 knockdown caused more rapid cell migration and increased the population of SV-HUC-1 and T24 cells in the G2-M phase. Conclusion: Our data suggest a close connection between aberrant ING4 expression and the carcinogenesis of human bladder cells. ING4 may be a potential target for bladder cancer chemotherapy.

Keywords:
Inhibitor of growth 4, Human bladder, Carcinogenesis, Cell migration, Cell cycle
1.
Piche B, Li G: Inhibitor of growth tumor suppressors in cancer progression. Cell Mol Life Sci 2010;67:1987-1999.
2.
Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, Ouchida M, Tsujigiwa H, Yamachika E, Fukushima K, Beder L, Hirohata S, Ninomiya Y, Nishizaki K, Shimizu K, Nagai N: Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 2005;356:109-117.
3.
Mathema VB, Koh YS: Inhibitor of growth-4 mediates chromatin modification and has a suppressive effect on tumorigenesis and innate immunity. Tumour Biol 2012;33:1-7.
4.
Wang QS, Li M, Zhang LY, Jin Y, Tong DD, Yu Y, Bai J, Huang Q, Liu FL, Liu A, Lee KY, Fu SB: Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology 2010;57:271-281.
5.
Xie Y, Zhang H, Sheng W, Xiang J, Ye Z, Yang J: Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Lett 2008;271:105-116.
6.
Cai L, Li X, Zheng S, Wang Y, Li H, Yang J, Sun J: Inhibitor of growth 4 is involved in melanomagenesis and induces growth suppression and apoptosis in melanoma cell line M14. Melanoma Res 2009;19:1-7.
7.
Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH, Jain RK: The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004;428:328-332.
8.
Russell M, Berardi P, Gong W, Riabowol K: Grow-ING, age-ING and die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 2006;312:951-961.
9.
Saha A, Bamidele A, Murakami M, Robertson ES: EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 2011;85:2079-2088.
10.
Zhang X, Wang KS, Wang ZQ, Xu LS, Wang QW, Chen F, Wei DZ, Han ZG: Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun 2005;331:1032-1038.
11.
Guo Q, Fast W: Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J Biol Chem 2011;286:17069-17078.
12.
Soliman MA, Riabowol K: After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci 2007;32:509-519.
13.
Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC: p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 2003;63:2373-2378.
14.
Coles AH, Gannon H, Cerny A, Kurt-Jones E, Jones SN: Inhibitor of growth-4 promotes IκB promoter activation to suppress NF-κB signaling and innate immunity. Proc Natl Acad Sci USA 2010;107:11423-11428.
15.
Kim S, Chin K, Gray JW, Bishop JM: A screen for genes that suppress loss of contact inhibition: Identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci USA 2004;101:16251-16256.
16.
Ozer A, Bruick RK: Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4. Cell Cycle 2005;4:1153-1156.
17.
Ozer A, Wu LC, Bruick RK: The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor. Proc Natl Acad Sci USA 2005;102:7481-7486.
18.
Zhang X, Lin DH, Jin Y, Wang KS, Zhang Y, Babilonia E, Wang Z, Giebisch G, Han ZG, Wang WH: Inhibitor of growth 4 (ING4) is upregulated by a low K intake and suppresses renal outer medullary K channels (ROMK) by MAPK stimulation. Proc Natl Acad Sci USA 2007;104:9517-9522.
19.
Zhang X, Xu LS, Wang ZQ, Wang KS, Li N, Cheng ZH, Huang SZ, Wei DZ, Han ZG: ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett 2004;570:7-12.
20.
Brat DJ, Bellail AC, Van Meir EG: The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 2005;7:122-133.
21.
Cai L, Li X, Zheng S, Wang Y, Wang Y, Li H, Yang J, Sun J: Inhibitor of growth 4 is involved in melanomagenesis and induces growth suppression and apoptosis in melanoma cell line M14. Melanoma Res 2009;19:1-7.
22.
Li M, Jin Y, Sun WJ, Yu Y, Bai J, Tong DD, Qi JP, Du JR, Geng JS, Huang Q, Huang XY, Huang Y, Han FF, Meng XN, Rosales JL, Lee KY, Fu SB: Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol 2009;219:87-95.
23.
Tapia C, Zlobec I, Schneider S, Kilic E, Guth U, Bubendorf L, Kim S: Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol 2011;42:983-990.
24.
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA: The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000;89:630-639.
25.
Ploeg M, Aben KKH, Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-293.
26.
Vishnu P, Mathew J, Tan WW: Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 2011;4:97-113.
27.
Zhang ZG, Ouyang J, Han CH, Yang JC, Yang HC, Long JH, Ding X: Growth inhibition and mechanisms of human bladder cancer T24 cells by adenovirus-mediated ING4 gene in vitro. Zhonghua Yi Xue Za Zhi 2010;90:3008-3013.
28.
Grignon DJ: The current classification of urothelial neoplasms. Mod Pathol 2009;22(suppl 2):S60-S69.
29.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-408.
30.
Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K, Pedeux R, Harris CC: Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin α1. Cancer Res 2007;67:2552-2558.
31.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
32.
Xie YF, Sheng W, Xiang J, Zhang H, Ye Z, Yang J: Adenovirus-mediated ING4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother Radiopharm 2009;24:261-269.
33.
Borkosky SS, Gunduz M, Beder L, Tsujigiwa H, Tamamura R, Gunduz E, Katase N, Rodriguez AP, Sasaki A, Nagai N, Nagatsuka H: Allelic loss of the ING gene family loci is a frequent event in ameloblastoma. Oncol Res 2010;18:509-518.
34.
Fang F, Luo LB, Tao YM, Wu F, Yang LY: Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18:409-416.
35.
Li Z, Xie Y, Sheng W, Miao J, Xiang J, Yang J: Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo. Cancer Biother Radiopharm 2010;25:427-437.
36.
Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W, Lane WS, Tan S, Yang XJ, Cote J: ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006;21:51-64.
37.
Saksouk N, Avvakumov N, Champagne KS, Hung T, Doyon Y, Cayrou C, Paquet E, Ullah M, Landry AJ, Cote V, Yang XJ, Gozani O, Kutateladze TG, Cote J: HBO1 HAT complexes target chromatin throughout gene coding regions via multiple PHD finger interactions with histone H3 tail. Mol Cell 2009;33:257-265.
38.
Wei Q, He W, Lu Y, Yao J, Cao X: Effect of the tumor suppressor gene ING4 on the proliferation of MCF-7 human breast cancer cells. Oncol Lett 2012;4:438-442.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.